Update on thyroid eye disease

Comprehensive Ophthalmology Update

Volumn 7, Issue 6, 2006, Pages 287-298

  Stemberger, Katrin ^a   Kahaly, George J ^a   Pitz, Susanne ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Management; Retrobulbar irradiation; Steroid therapy; Thyroid eye disease

Indexed keywords

AZATHIOPRINE; BOTULINUM TOXIN; CARBIMAZOLE; CIAMEXON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; METHYLPREDNISOLONE; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DECOMPRESSION SURGERY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; ELECTIVE SURGERY; ENDOCRINE OPHTHALMOPATHY; HISTOPATHOLOGY; HUMAN; LIVER FAILURE; PATHOGENESIS; REVIEW; SURGICAL TECHNIQUE; THYROIDECTOMY; EYE SURGERY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY;

AUTOIMMUNE DISEASES; COMBINED MODALITY THERAPY; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; OPHTHALMOLOGIC SURGICAL PROCEDURES; RADIOTHERAPY;

EID: 33947503651     PISSN: 15277313     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Burch HB, Wartofsky L: Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14: 747-93, 1993
2. Gerding MN, Terwee CB, Dekker FW, et al: Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7: 885-9, 1997
3. Bahn RS, Heufelder AE: Pathogenesis of Graves' ophthalmopathy N Engl J Med 329: 1468-75, 1993
4. Gorman CA: Pathogenesis of Graves' ophthalmopathy. Thyroid 4: 379-83, 1994
5. Bartalena L, Marcocci C, Pinchera A: Treating severe Graves' ophthalmopathy. Baillieres Clin Endocrinol Metab 11: 521-36, 1997
6. Heufelder AE: Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol 132: 532-41, 1995
7. Bartalena L, Pinchera A, Marcocci C: Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21: 168-99, 2000
8. Heufelder AE: Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 1:87-95, 2000
9. Ludgate M, Baker G: Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 127:193-8, 2002
10. Wiersinga WM, Prummel MF: Pathogenesis of Graves' ophthalmopathy - current understanding. J Clin Endocrinol Metab 86: 501-3, 2001
11. Wakelkamp IM, Bakker O, Baldeschi L, et al: TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 58:280-7, 2003
12. Smith TJ: Novel aspects of orbital fibroblast pathology. J Endocrinol Invest 27:246-53, 2004
13. Konishi J, Herman MM, Kriss JP: Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane. Endocrinology 95: 434-46, 1974
14. Marinò M, Lisi S, Pinchera A, et al: Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Thyroid 13: 851-9, 2003
15. Marinò M, Chiovato L, Lisi S, et al: Role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 27: 230-6, 2004
16. Weetman AP, Cohen S, Gatter KC, et al: Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 75: 222-7, 1989
17. Davies TF: Seeing T cells behind the eye. Eur J Endocrinol 132: 264-5, 1995
18. Valyasevi RW, Jyonouchi SC, Dutton CM, et al: Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 86: 903-8, 2001
19. Rootman J, Patel S, Berry K, et al: Pathological and clinical study of Müller's muscle in Graves' ophthalmopathy. Can J Ophthalmol 22: 32-6, 1987
20. Cockerham KP, Hidayat AA, Brown HG, et al: Clinicopathologic evaluation of the Mueller muscle in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg 18:11-7, 2002
21. Grove AS: Upper eyelid retraction and Graves' disease. Ophthalmology 88: 499-506, 1981
22. Kazim M, Goldberg RA, Smith TJ: Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 120: 380-6, 2002
23. Soares-Welch CV, Fatourechi V, Bartley GB, et al: Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients. Am J Ophthalmol 136: 433-41, 2003
24. Chang EL, Bernardino CR, Rubin PA: Transcaruncular orbital decompression for management of compressive optic neuropathy in thyroid-related orbitopathy. Plast Reconstr Surg 112: 739-47, 2003
25. Acaroolu G, Simbek T, Ozalp S, et al: Subclinical optic neuropathy in Graves' orbitopathy. Jpn J Ophthalmol 47: 459-62, 2003
26. Giaconi JA, Kazim M, Rho T, et al: CT scan evidence of dysthyroid optic neuropathy. Ophthal Plast Reconstr Surg 18: 177-82, 2002
27. Lucarelli MJ, Shore JW: Management of thyroid optic neuropathy. Int Ophthalmol Clin 36: 179-93, 1996
28. Henderson JW: Optic neuropathy of exophthalmic goiter (Graves' disease). AMA Arch Ophthalmol 59: 471-80, 1958
29. Kennerdell JS, Rosenbaum AE, El-Hoshy MH: Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography. Arch Ophdialmol 99: 807-9, 1981
30. Neigel JM, Rootman J, Belkin RI, et al: Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 95: 1515-21, 1988
31. Ambrosio G, Ferrara G, Vitale R, et al: Visual evoked potentials in patients with Graves' ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropauhy. Doc Ophthalmol 106: 99-104, 2003
32. Trokel SL, Jakobiec FA: Correlation of CT scanning and pathologic features of ophthalmic Graves' disease. Ophthalmology 88: 553-64, 1981
33. Dresner SC, Kennerdell JS: Dysthyroid orbitopathy. Neurology 35: 1628-34, 1985
34. Kahaly GJ: Imaging in thyroid-associated orbitopathy. Eur J Endocrinol 145: 107-18, 2001
35. Hurwitz JJ, Freeman JL, Eplett CJ, et al: Ethmoidectomy decompression for the treatment of Graves' optic neuropathy. Can J Ophthalmol 27: 283-7, 1992
36. Trobe JD, Glaser JS, Laflamme P: Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol 96: 1199-1209, 1978
37. Nugent RA, Belkin RI, Neigel JM, et al: Graves orbitopathy: correlation of CT and clinical findings. Radiology 177: 675-82, 1990
38. Glatt HJ: Optic nerve dysfunction in thyroid eye disease: a clinician's perspective. Radiology 200: 26-7, 1996
39. Kazim M, Trokel SL, Acaroglu G, et al: Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br J Ophthalmol 84: 600-5, 2000
40. Anderson RL, Tweeten JP, Patrinely JR, et al: Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg 20: 568-74, 1989
41. Barrett L, Glatt HJ, Burde RM, et al: Optic nerve dysfunction in thyroid eye disease: CT. Radiology 167: 503-7, 1988
42. Hudson HL, Levin L, Feldon SE: Graves exophthalmos unrelated to extraocular muscle enlargement. Superior rectus muscle inflammation may induce venous obstruction. Ophthalmology 98: 1495-9, 1991
43. Birchall D, Goodall KL, Noble JL, et al: Graves ophthalmopathy: intracranial fat prolapse on CT images as an indicator of optic nerve compression. Radiology 200: 123-7, 1996
44. Lazarus JH, McKeag D, Lane C, et al: Clinical features of dysthyroid optic neuropathy: a European group on Graves' orbitopathy (EUGOGO) survey. Br J Ophthalmol [Epub ahead of print], 2006
45. Perros P, Crombie AL, Kendall-Taylor P: Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42: 45-50, 1995
46. Bardey GB, Fatourechi V, Kadrmas EF, et al: Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284-90, 1996
47. Bartley GB, Fatourechi V, Kadrmas EF, et al: The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 120: 511-7, 1995
48. Mourits MP, Prummel MF, Wiersinga WM, et al: Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47: 9-14, 1997
49. Weetman AP, Wiersinga WM: Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol (Oxf) 49: 21-8, 1998
50. _: Classification of eye changes of Graves' disease. Thyroid 2: 235-6, 1992
51. Weetman AP, Holt ME, Campbell AK, et al: Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J (Clin Res Ed) 288: 518-20, 1984
52. Weetman AP: The immunomodulatory effects of antithyroid drugs. Thyroid 4: 145-6, 1994
53. DeGroot LJ: Radioiodine and the immune system. Thyroid 7: 259-64, 1997
54. Tallstedt L, Lundell G, Tørring O, et al: Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326: 1733-8, 1992
55. Bartalena L, Marcocci C, Bogazzi F, et al: Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopadiy. N Engl J Med 338: 73-8, 1998
56. Marcocci C, Bartalena L, Pinchera A: Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?. J Endocrinol Invest 21: 468-71, 1998
57. Winsa B, Rastad J, Akerström G, et al: Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy. Eur J Endocrinol 132: 406-12, 1995
58. Bartalena L, Marocci C, Bogazzi F, et al: Glucocorticoid therapy of Graves' ophthalmopathy. Exp Clin Endocrinol 97: 320-7, 1991
59. Bonnema SJ, Bartalena L, Toft AD, et al: Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 147: 1-11, 2002
60. Kazim M, Trokel S, Moore S: Treatment of acute Graves orbitopathy. Ophthalmology 98: 1443-8, 1991
61. Perry JD, Kadakia A, Foster JA: Transcaruncular orbital decompression for dysthyroid optic neuropathy. Ophthal Plast Reconstr Surg 19: 353-8, 2003
62. Kacker A, Kazim M, Murphy M, et al: "Balanced" orbital decompression for severe Graves' orbitopathy: technique with treatment algorithm. Otolaryngol Head Neck Surg 128: 228-35, 2003
63. Smith TJ: Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J Clin Invest 74: 2157-63, 1984
64. Smith TJ, Bahn RS, Gorman CA: Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts. J Clin Endocrinol Metab 69: 1019-23, 1989
65. Tagami T, Tanaka K, Sugawa H, et al: High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J 43: 689-99, 1996
66. Matejka G, Verges B, Vaillant G, et al: Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Horm Metab Res 30: 93-8, 1998
67. Guy JR, Fagien S, Donovan JP, et al: Memylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 96: 1048-52; discussion 1052-3, 1989
68. Boulos PR, Hardy I: Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 15: 389-400, 2004
69. Marcocci C, Bartalena L, Panicucci M, et al: Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 27: 33-42, 1987
70. Kahaly G, Schrezenmeir J, Krause U, et al: Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16: 415-22, 1986
71. Kahaly GJ, Pitz S, Hommel G, et al: Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90: 5234-40, 2005
72. Marcocci C, Bartalena L, Tanda ML, et al: Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562-7, 2001
73. Bartalena L, Marcocci C, Tanda ML, et al: An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 28: 469-78, 2005
74. Bartalena L, Marcocci C, Tanda L, et al: Management of thyroid eye disease. Eur J Nucl Med Mol Imaging 29 Suppl 2: S458-65, 2002
75. Hart RH, Kendall-Taylor P, Crombie A, et al: Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 21: 328-36, 2005
76. Marino M, Morabito E, Brunetto MR, et al: Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14: 403-6, 2004
77. Woloschak GE, Chang-Liu CM: Differential modulation of specific gene expression following high- and low-LET radiations. Radiat Res 124: 183-7, 1990
78. Rodemann HP, Bamberg M: Cellular basis of radiation-induced fibrosis. Radiother Oncol 35: 83-90, 1995
79. Smitt MC, Donaldson SS: Radiation therapy for benign disease of the orbit. Semin Radiat Oncol 9: 179-89, 1999
80. Beckendorf V, Maalouf T, George JL, et al: Place of radiotherapy in the treatment of Graves' orbitopathy. Int J Radiat Oncol Biol Phys 43: 805-15, 1999
81. Donaldson SS, Bagshaw MA, Kriss JP: Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 37: 276-85, 1973
82. Bartalena L, Marcocci C, Chiovato L, et al: Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56: 1139-44, 1983
83. Marcocci C, Bartalena L, Rocchi R, et al: Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 88: 3561-6, 2003
84. Kahaly GJ, Rösler HP, Pitz S, et al: Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 85: 102-8, 2000
85. Gerling J, Kommerell G, Henne K, et al: Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol BiolPhys 55: 182-9, 2003
86. Bartalena L, Marcocci C, Tanda ML, et al: Orbital radiotherapy for Graves' ophthalmopathy. Thyroid 12: 245-50, 2002
87. Nygaard B, Specht L: Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy. Lancet 351: 725-6, 1998
88. Yuen AP, Kwan KY, Chan E, et al: Endoscopic transnasal orbital decompression for thyrotoxic orbitopathy. Hong Kong Med J 8: 406-10, 2002
89. Bartley GB, Fatourechi V, Kadrmas EF, et al: Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121: 426-34, 1996
90. Felberg NT, Sergott RC, Savino PJ, et al: Lymphocyte subpopulations in Graves' ophthalmopathy. Arch Ophthalmol 103: 656-9, 1985
91. Prummel MF, Mourits MP, Berghout A, et al: Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 321: 1353-9, 1989
92. Raikow RB, Dalbow MH, Kennerdell JS, et al: Immunohistochemical evidence for IgE involvement in Graves' orbitopathy. Ophthalmology 97: 629-35, 1990
93. Strakosch CR, Wenzel BE, Row VV, et al: Immunology of autoimmune thyroid diseases. N Engl J Med 307: 1499-507, 1982
94. Smith BR, Hall R: Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 2: 427-31, 1974
95. Prummel MF, Wiersinga WM, Mourits MP, et al: Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150: 1098-101, 1990
96. Krassas GE: Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 27: 281-7, 2004
97. Dickinson AJ, Vaidya B, Miller M, et al: Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89: 5910-5, 2004
98. Wémeau JL, Caron P, Beckers A, et al: Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 90: 841-8, 2005
99. Stan MN, Garrity JA, Bradley EA, et al: Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of graves' ophthalmopathy. J Clin Endocrinol Metab 91: 4817-24, 2006
100. Bartalena L, Martino E, Marcocci C, et al: More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 12: 733-7, 1989
101. Pfeilschifter J, Ziegler R: Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45: 477-81, 1996
102. Prummel MF, Wiersinga WM: Smoking and risk of Graves' disease. JAMA 269:479-82, 1993
103. Mack WP, Stasior GO, Cao HJ, et al: The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves ophthalmopathy. Ophthal Plast Reconstr Surg 15: 260-71, 1999
104. Utiger RD: Effects of smoking on thyroid function. Eur J Endocrinol 138: 368-9, 1998
105. Vaseghi M, Tarin TT, Levin PS, et al: Minimally invasive orbital decompression for Graves' ophthalmopadiy. Ann Otol Rhinol Laryngol 112: 57-62, 2003
106. Paridaens D, Lie A, Grootendorst RJ, et al: Efficacy and side effects of 'swinging eyelid' orbital decompression in Graves' orbitopathy: a proposal for standardized evaluation of diplopia. Eye 20: 154-62, 2006
107. Kikkawa DO, Pornpanich K, Cruz RC, et al: Graded orbital decompression based on severity of proptosis. Ophthalmology 109: 1219-24, 2002
108. Olivari N: Transpalpebral decompression of endocrine ophthalmopathy (Graves' disease) by removal of intraorbital fat: experience with 147 operations over 5 years. Plast Reconstr Surg 87: 627-41; discussion 642-3, 1991
109. Trokel S, Kazim M, Moore S: Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology 100: 674-82, 1993
110. Looi AL, Luu CD, Wong TY, et al: Factors associated with decompression and strabismus surgery in thyroid eye disease. Ann Acad Med Singapore 34: 154-7, 2005
111. Baldeschi L, MacAndie K, Hintschich C, et al: The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am J Ophthalmol 140: 642-7, 2005
112. Unal M, Leri F, Konuk O, et al: Balanced orbital decompression combined with fat removal in Graves ophthalmopathy: do we really need to remove the third wall?. Ophthal Plast Reconstr Surg 19: 112-8, 2003
113. Leone CR, Piest KL, Newman RJ: Medial and lateral wall decompression for thyroid ophthalmopathy. Am J Ophthalmol 108: 160-6, 1989
114. Goldberg RA, Kim AJ, Kerivan KM: The lacrimal keyhole, orbital door jamb, and basin of the inferior orbital fissure. Three areas of deep bone in the lateral orbit. Arch Ophthalmol 116: 1618-24, 1998
115. Goldberg RA, Perry JD, Hortaleza V, et al: Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy. Ophthal Plast Reconstr Surg 16: 271-7, 2000
116. Adenis JP, Robert PY, Boncoeur-Martel MP: Abnormalities of orbital volume. Eur J Ophthalmol 12: 345-50, 2002
117. Köse S, Uretmen O, Emre S, et al: Recession of the inferior rectus muscle under topical anesthesia in thyroid ophthalmopathy. J Pediatr Ophthalmol Strabismus 39: 331-5, 2002
118. Flanders M, Hastings M: Diagnosis and surgical management of strabismus associated with thyroid-related orbitopathy. J Pediatr Ophthalmol Strabismus 34: 333-40, 1997
119. Fells P, Kousoulides L, Pappa A, et al: Extraocular muscle problems in thyroid eye disease. Eye 8 (Pt 5): 497-505, 1994
120. Wiersinga WM: Perspective - Part III: retrobulbar irradiation in Graves orbitopathy: the Dutch experience. Ophthal Plast Reconstr Surg 18: 175-6, 2002
121. Evans D, Kennerdell JS: Extraocular muscle surgery for dysthyroid myopathy. Am J Ophthalmol 95: 767-71, 1983
122. Sprunger DT, Helveston EM: Progressive overcorrection after inferior rectus recession. J Pediatr Ophthalmol Strabismus 30: 145-8, 1993
123. Scott AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87: 1044-9, 1980
124. Sharma P, Reinecke RD: Single-stage adjustable strabismus surgery for restrictive strabismus. J AAPOS 7: 358-62, 2003
125. Mourits MP, Koorneef L, van Mourik-Noordenbos AM, et al: Extraocular muscle surgery for Graves' ophthalmopathy: does prior treatment influence surgical outcome?. Br J Ophthalmol 74: 481-3,1990
126. Ruttum MS: Effect of prior orbital decompression on outcome of strabismus surgery in patients with thyroid ophthalmopathy. J AAPOS 4: 102-5, 2000
127. Chuenkongkaew W: Botulinum toxin treatment for upper lid retraction of dysthyroidism. J Med Assoc Thai 86: 1051-4, 2003
128. Ebner R: Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy. J Clin Neuroophthalmol 13: 258-61, 1993
129. Uddin JM, Davies PD: Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 109: 1183-7, 2002
130. Putterman AM: Thyroid ophthalmopathy: surgical management. Curr Ther Endocrinol Metab 6: 85-90, 1997
131. Mourits MP, Sasim IV: A single technique to correct various degrees of upper lid retraction in patients with Graves' orbitopathy. Br J Ophthalmol 83: 81-4, 1999
132. Hintschich C, Haritoglou C: Full thickness eyelid transsection (blepharotomy) for upper eyelid lengthening in lid retraction associated with Graves' disease. Br J Ophthalmol 89: 413-6, 2005
133. Lyons CJ, Vickers SF, Lee JP: Botulinum toxin therapy in dysthyroid Strabismus. Eye 4 (Pt 4): 538-42, 1990
134. Dunn WJ, Arnold AC, O'Connor PS: Botulinum toxin for the treatment of dysthyroid ocular myopathy. Ophthalmology 93: 470-5, 1986
135. Simonsz HJ, Kommerell G: Increased muscle tension and reduced elasticity of affected muscles in recent-onset Graves' disease caused primarily by active muscle contraction. Doc Ophthalmol 72: 215-24, 1989